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Introduction
In Taiwan, children with malignancies who need chemo-
therapy management are treated according to Taiwan
Pediatric Oncology Group (TPOG) protocols. Under
the individual protocols, those children ought to receive
intravenous fluid hydration, serum alkalization and the
administration of various chemotherapy agents. Some
chemotherapy agents, especially anthracycline, have been
demonstrated to be associated with cardiotoxicity asso-
ciated with delayed myocardial damage that depends
on the accumulated dosage.1,2 However, information
on the influence of chemotherapy agents on cardiac
function in children with malignancies is limited. The
purpose of this study was to determine the change in
left ventricular (LV) function in children with malig-
nancies undergoing long-term chemotherapy.
Methods
Study population
A total of 19 pediatric patients (mean age, 12.5 ± 4.6
years; 11 males, 8 females) with malignancies were
enrolled. We divided the patients into 2 groups: (1) an
osteogenic sarcoma (OGS) group (n = 12; Group I);
and (2) a non-osteogenic sarcoma (non-OGS) group
(n=7; Group II), which included acute lymphoblastic/
myeloblastic leukemia (ALL/AML, n = 4), neuro-
blastoma (NB, n = 2) and non-Hodgkin’s lymphoma
(NHL, n = 1). All children had received standard che-
motherapy using the TPOG protocol with or without
low-to-moderate doses of anthracycline (for osteogenic
sarcoma).3 The accumulated dosages of anthracycline
in Group I and II patients were 144.3 ± 56.4 mg/M2
and 131.7 ± 105.5 mg/M2 (p = 0.735), respectively.
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After completion of the entire chemotherapy course,
the children received echocardiography to investigate
the various parameters of LV systolic function, diastolic
function, and myocardial performance index (MPI).
We compared the systolic and diastolic parameters of
LV function and MPI between the 2 groups.
Echocardiographic examination
Complete 2-dimensional spectral Doppler and color
flow Doppler examinations were performed in all
patients. The Doppler measurements were performed
using a 4- or 8-MHz transducer as appropriate for
patient size, and an HP ultrasound system (Hewlett
Packard M2424A) was utilized. The Doppler signals
were displayed at a paper speed of 100 m/s. The 
basic indicators of systolic function, including LV
ejection fraction/fractional shortening (EF/FS), and
rate-corrected mean velocity of the circumferential
fiber shortness (Vcf) were measured according to 
the recommendations of the American Society of
Echocardiography.4
The indicators of diastolic function for the trans-
mitral peak velocities of early (E) and late (A) diastole,
E/A ratio, and deceleration time (DT) were meas-
ured by pulse-wave Doppler technique.5 The specific
time intervals measured for delivering the MPI (Tei
index) are shown in Figure 1. The Doppler intervals
were measured in a 4-chamber apical scan plane for
interval “a” (from the cessation to onset of the mitral
inflow), and in the 5-chamber apical view, scan plane
was also performed for interval “b” (equal to the ejec-
tion time; ET). MPI was defined as the sum of the
isovolumic contraction time (ICT) and isovolumic relax-
ation time (IRT) divided by the ejection time (ET),
i.e. MPI = (ICT + IRT)/ET; MPI = (a − b)/b. ICT
was calculated from the cessation of mitral inflow to
the onset of aortic outflow. IRT was calculated from
the cessation of aortic outflow to the onset of mitral
inflow. To account for any slight variation in the R-R
cycle length, each time interval was measured for 3–5
consecutive beats and then averaged.
Statistical analysis
All data are expressed as mean ± standard deviation
(SD). Student’s t test was used for statistical analyses
and comparisons between the 2 groups. Collected data
that were not normally distributed were compared
using the Mann-Whitney Rank Sum test. Statistical
significance was defined as p < 0.05.
Results
Patient characteristics
The clinical characteristics are presented in Table 1.
The 19 patients (11 males, 8 females) had a mean age of
12.5 ± 4.6 years, mean body weight of 39.8 ± 15.6 kg,
mean height of 146.0 ± 22.9 cm and mean body mass
index (BMI) of 1.77 ± 0.32. There were no statistical
differences in the body weight, height or BMI between
Group I and Group II patients, but Group II patients
were younger (14.4 ± 3.6 vs. 9.2 ± 4.5 years old; p =
0.015). While the study reported that all the patients
in the OGS group had completed neoadjuvant che-
motherapy, 9 had undergone the TPOG protocol with
no lung metastases and 3 had completed the TPOG
protocol with lung metastases. Four patients with ALL/
AML who had undergone the TPOG protocol were
in complete remission (2 AML patients underwent
peripheral blood stem cell transplantations). The other
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IRT = c − d; ICT = (a − b) − IRT
MPI = (IRT + ICT)/ET = (a − b)/b
Figure 1. Doppler intervals were measured in a 4-chamber apical scan plane for interval “a” (from the cessation to onset of the mitral
inflow), and in the 5-chamber apical view, scan plane was also performed for interval “b” (equal to the ejection time; ET). Myocardial
performance index (MPI) was defined as the sum of the isovolumic contraction time (ICT) and isovolumic relaxation time (IRT) divided by
the ejection time (ET), i.e. MPI = (ICT+IRT)/ET; MPI = (a – b)/b. To account for a slight variation in the R-R cycle length, each time interval
was measured for 3–5 consecutive beats and then averaged. Interval “c” is from the R-wave to the onset of mitral inflow, and interval
“d” is from the R-wave to the cessation of left ventricular outflow. Associated with “c” and “d”, we could calculate IRT by the formula
IRT = c – d.
2 with neuroblastomas were kept on consolidation
therapy and were also in complete remission. The 1
patient with non-Hodgkin’s-type lymphoma had been
receiving the TPOG protocol and was in partial remis-
sion. Mean overall follow-up was 8.36 months (range,
1–18 months).
Echocardiographic examinations
Table 2 summarizes the echocardiographic data of LV
systolic and diastolic function. Nineteen patients had
normal LV systolic function with LVEF 72.0 ± 5.7%,
LVFS 40 ± 4.8% and rate-corrected mean Vcf 1.55 ±
0.20 circumferences/s. However, there was a trend
towards higher E/A ratio (1.71 ± 0.37) and shorter
DT (140.3 ± 40.6 ms) in the patients receiving chemo-
therapy, but there was no statistically significant dif-
ference in E/A ratio and DT between the 2 individual
groups. A significantly lower MPI (0.23 ± 0.06) with
a tendency toward a shorter IRT (42.00 ± 19.14 ms)
and shorter ICT (18.15 ± 9.74 ms) was also observed
in these patients. Furthermore, Group I patients had
an even lower MPI when compared with Group II
patients (0.20 ± 0.02 vs. 0.28 ± 0.07; p = 0.031).
Discussion
According to previously published literature, anthra-
cycline is the most common chemotherapy agent that
may induce myocardial damage leading to systolic
and diastolic dysfunction depending on the total accu-
mulated dosage.2,6,7 Dr Lubomir demonstrated the
negative influence on the heart after anthracycline treat-
ment in a study that included a total of 12 patients
(8%) with LV systolic dysfunction (LVEF < 55%; LVFS
< 30%).1 According to a previous report by Billingham
et al, it was determined that anthracycline cardiomyo-
pathy developed on the basis of the structural changes
observed in all the myocytes, which lead to subsequent
vacuolation of the cytoplasm, myofibril wastage and
fibrous degeneration of the myocardium.8 All those
changes had a linear relationship to the cumulative
dosage of anthracycline, especially with high doses
> 400–500 mg/M2.1,2,9 However, all the patients in
our study had normal LV systolic function assessed 
by echocardiography (normal LVEF, LVFS and rate-
corrected mean Vcf). The reason was possibly due to
there not being a high enough cumulative dosage of
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Table 1. Demographic data of patients in the osteogenic sarcoma group (Group I) and the non-osteogenic sarcoma group (Group II)
All Group I Group II p (Group I vs. II)
Age (yr) 12.5 ± 4.6 14.4 ± 3.6 9.2 ± 4.5 0.015*
Gender (male/female) 11/8 7/5 4/3 0.661
Body weight (kg) 39.7 ± 15.6 43.5 ± 12.9 33.5 ± 18.7 0.187
Height (cm) 146.0 ± 22.9 155.0 ± 14.8 130.5 ± 27.1 0.057
Body mass index 1.77 ± 0.32 1.76 ± 0.32 1.79 ± 0.36 0.875
*Significant difference.
Table 2. Parameters of left ventricular systolic and diastolic function in the osteogenic sarcoma group (Group I) and the non-osteogenic
sarcoma group (Group II)
All Group I Group II p (Group I vs. II)
Systolic parameters
LVEF (%) 72.0 ± 5.7 73.0 ± 6.1 70.3 ± 5.1 0.314
LVFS (%) 40 ± 4.8 40.7 ± 4.8 38.9 ± 4.9 0.448
Mean Vcf (1/s) 1.55 ± 0.20 1.54 ± 0.25 1.56 ± 0.31 0.923
Diastolic parameters
E/A ratio 1.71 ± 0.37 1.72 ± 0.4 1.69 ± 0.3 0.911
DT (ms) 140.3 ± 40.6 155.1 ± 42.1 114.9 ± 22.6 0.099
MPI 0.23 ± 0.06 0.20 ± 0.02 0.28 ± 0.07 0.031*
IRT (ms) 42.00 ± 19.14 36.52 ± 13.63 51.38 ± 24.42 0.220
ICT (ms) 18.15 ± 9.74 17.77 ± 8.43 18.81 ± 12.40 1.00
ET (ms) 261.03 ± 28.83 265.16 ± 24.54 253.95 ± 36.01 0.429
*Significant difference. LVEF = left ventricular ejection fraction; LVFS = left ventricular fractional shortening; Vcf = velocity of the circumferential fiber shortness;
DT = deceleration time; MPI = myocardial performance index; IRT = isovolumic relaxation time; ICT = isovolumic contraction time; ET = ejection time.
anthracycline in our patients. On the other hand, the
significantly higher E/A ratio, shorter DT and shorter
IRT demonstrated that the LV diastolic dysfunction
was the result of a restricted filling pattern in both
groups, but there was no statistically significant dif-
ference between the 2 groups. The results may imply
that the reduced left ventricle compliance might not
be completely attributed to anthracycline cardiotoxicity
in the TPOG protocol in these patients, but could be
associated with long-term fluid overloading or other
chemotherapy agents.
MPI was first described by Dr Tei Chuwa in 1995
as a noninvasive Doppler measurement of the global
(systolic and diastolic) ventricular function, and its nor-
mal range was 0.33 ± 0.02 for those aged between 3
and 18 years old.10–12 A broad range of applications in
cardiology were established in the literature, including
those for congenital heart disease, valvular heart dis-
ease, cardiomyopathy, heart failure, pulmonary hyper-
tension and cardiotoxicity from chemotherapy.13–17
In the present study, both groups of children had a
relatively low MPI (0.23 ± 0.06) with a relatively short
IRT associated with a restricted filling pattern. The
results were different from the effects of anthracycline
on MPI observed by Ishii et al.17 They reported a sig-
nificantly higher MPI value (0.45 ± 0.06) associated
with a prolongation of the IRT and ICT, and a con-
siderable shortening of the ET in 30 patients admin-
istered moderate to high doses of anthracycline. By
comparing the 2 patient groups in the present study,
there was a statistical difference in MPI, but no differ-
ences in IRT, ICT and ET. These findings imply that
there was no significant anthracycline-related cardio-
toxicity in the children in this study because of the
low accumulated dosage. However, a lower MPI in
the patients in the OGS group was demonstrated, and
further investigation is needed to explore possible
reasons for this.
As only a limited number of patients were enrolled
in these 2 groups, more studies are needed to investigate
LV dysfunction in children undergoing chemotherapy
with anthracycline.
We conclude that children with malignancies who
underwent chemotherapy according to the TPOG pro-
tocol had normal LV systolic function. We also demon-
strated LV diastolic dysfunction with a restricted filling
pattern and shorter IRT, higher E/A ratio and shorter
DT. The shorter IRT resulted in a lower MPI in all the
children, especially in the OGS group. Fortunately, no
significant evidence of anthracycline-related cardio-
toxicity was found in any of the children undergoing
chemotherapy according to the TPOG protocol in
this study.
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